PURPOSE: This study was aimed to investigate the prevalence of serologic markers of celiac disease in Tunisian patients with trisomy 21. METHODS: Twenty seven patients with trisomy 21 were prospectively screened by indirect immunofluorescence for anti-reticulin and anti-endomysium antibodies, and by an ELISA method for anti-gliadin and anti-transglutaminase antibodies. None of the 27 patients had known celiac disease at the time of the study. RESULTS: Anti-reticulin, anti-endomysium, anti-gliadin and anti-transglutaminase antibodies were found in respectively 11%, 11%, 18.5%, and 14.8% of cases. Only one patient with all serologic markers of celiac disease underwent biopsy which shows a villous atrophy. CONCLUSION: Anti-endomysium and anti-transglutaminase antibodies are good immunologic markers for the screening for celiac disease, a screening which is justified in patient with trisomy 21. Copyright John Libbey Eurotext 2003
PURPOSE: This study was aimed to investigate the prevalence of serologic markers of celiac disease in Tunisian patients with trisomy 21. METHODS: Twenty seven patients with trisomy 21 were prospectively screened by indirect immunofluorescence for anti-reticulin and anti-endomysium antibodies, and by an ELISA method for anti-gliadin and anti-transglutaminase antibodies. None of the 27 patients had known celiac disease at the time of the study. RESULTS: Anti-reticulin, anti-endomysium, anti-gliadin and anti-transglutaminase antibodies were found in respectively 11%, 11%, 18.5%, and 14.8% of cases. Only one patient with all serologic markers of celiac disease underwent biopsy which shows a villous atrophy. CONCLUSION: Anti-endomysium and anti-transglutaminase antibodies are good immunologic markers for the screening for celiac disease, a screening which is justified in patient with trisomy 21. Copyright John Libbey Eurotext 2003